These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33590710)

  • 1. Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma.
    Jeong H; Im HS; Bang Y; Kim YH; Kim HR; Lee HJ; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Lee JH; Ahn JY; Na HK; Ryu JS; Kang J; Kim SB; Kim JH; Park SR
    Cancer Med; 2021 Mar; 10(5):1745-1758. PubMed ID: 33590710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.
    Sugawara K; Yagi K; Okumura Y; Nishida M; Aikou S; Yamashita H; Yamashita H; Seto Y
    Int J Clin Oncol; 2020 Apr; 25(4):552-560. PubMed ID: 31828451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer.
    Wu SX; Li XY; Xu HY; Xu QN; Luo HS; Du ZS; Huang HC; Wu ZY
    Sci Rep; 2017 Dec; 7(1):16870. PubMed ID: 29203855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
    Zhao Z; Zhang Y; Wang X; Geng X; Zhu L; Li M
    Cancer Med; 2020 Aug; 9(16):5881-5888. PubMed ID: 32627960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
    Dai H; Shao YW; Tong X; Wu X; Pang J; Feng A; Yang Z
    Cancer Med; 2020 Mar; 9(5):1628-1637. PubMed ID: 31851786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Yap WK; Chang YC; Hsieh CH; Chao YK; Chen CC; Shih MC; Hung TM
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):689-698. PubMed ID: 29188300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma.
    Qiu B; Wang D; Yang H; Xie W; Liang Y; Cai P; Chen Z; Liu M; Fu J; Xie C; Liu H
    Radiother Oncol; 2016 Nov; 121(2):239-245. PubMed ID: 27793445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcome of esophagectomy and chemoradiotherapy for resectable esophageal squamous cell carcinoma in patients >75 years of age.
    Mayanagi S; Inoue M; Tokizawa K; Fushiki K; Tsushima T; Yokota T; Yamazaki K; Yasui H; Tsubosa Y
    Thorac Cancer; 2024 Jul; 15(21):1656-1664. PubMed ID: 38898742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment clinical stage predicts locoregional recurrence in patients with esophageal cancer who achieved a complete clinical response to chemoradiotherapy.
    Liw PX; Wen YW; Tsai CY; Chang HK; Tseng CK; Hung TM; Chao YK
    J Thorac Cardiovasc Surg; 2018 May; 155(5):2233-2242.e2. PubMed ID: 29397973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of patients with recurrent squamous cell carcinoma of the esophagus undergoing salvage endoscopic resection after definitive chemoradiotherapy.
    Ego M; Abe S; Nakatani Y; Nonaka S; Suzuki H; Yoshinaga S; Oda I; Kato K; Honma Y; Itami J; Daiko H; Saito Y; Boku N
    Surg Endosc; 2021 Apr; 35(4):1766-1776. PubMed ID: 32356109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival after definitive chemoradiotherapy for patients with esophageal cancer: a retrospective cohort study.
    van der Zijden CJ; Bouwman A; Mostert B; Nuyttens JJME; van der Sluis PC; Spaander MCW; Mens JWM; Homs MYV; van Doorn L; Wijnhoven BPL; Lagarde SM
    Dis Esophagus; 2024 Oct; 37(10):. PubMed ID: 38836354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy.
    Okamoto H; Fujishima F; Kamei T; Nakamura Y; Ozawa Y; Miyata G; Nakano T; Katsura K; Abe S; Taniyama Y; Sakurai T; Teshima J; Hikage M; Sasano H; Ohuchi N
    BMC Cancer; 2015 Mar; 15():208. PubMed ID: 25880782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
    Wang BY; Wu SC; Chen HC; Hung WH; Lin CH; Huang CL; Chen HS
    Br J Surg; 2019 Feb; 106(3):255-262. PubMed ID: 30395362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
    Kawakami T; Tsushima T; Omae K; Ogawa H; Shirasu H; Kito Y; Yoshida Y; Hamauchi S; Todaka A; Machida N; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
    BMC Cancer; 2018 May; 18(1):573. PubMed ID: 29776344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of Failure Following Dose-escalated Chemoradiotherapy for Fluorodeoxyglucose Positron Emission Tomography Staged Squamous Cell Carcinoma of the Oesophagus.
    Effeney R; Shaw T; Burmeister BH; Burmeister E; Harvey J; Mai GT; Thomas J; Barbour AP; Smithers BM; Pryor DI
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):642-649. PubMed ID: 30017206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Chen M; Shen M; Lin Y; Liu P; Liu X; Li X; Li A; Yang R; Ni W; Zhou X; Zhang L; Xu B; Lin J; Chen J; Tian Y
    Radiat Oncol; 2018 Aug; 13(1):150. PubMed ID: 30111361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: A retrospective study.
    Jo YY; Yu J; Song KJ; Jang JY; Yoo YJ; Kim SB; Park SR; Kim YH; Kim HR; Kim JH
    Radiother Oncol; 2021 Sep; 162():112-118. PubMed ID: 34265356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
    Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Zhou XL; Li YQ; Zhu WG; Yu CH; Song YQ; Wang WW; He DC; Tao GZ; Tong YS
    Sci Rep; 2017 Feb; 7():42581. PubMed ID: 28195186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.